Intelligence Platform
Patents
Browse 991 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 12186306
Methods of treatment for cystic fibrosis
granted patentUS 12173337
Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and m
granted patentUS 12173324
Differentiation of pancreatic endocrine cells
granted patentUS 12168009
Modulators of cystic fibrosis transmembrane conductance regulator
granted patentUS 12161674
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
granted patentUS 12134767
Materials and methods for treatment of hemoglobinopathies
granted patentUS 12129471
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
granted patentUS 12121524
DNA-PK inhibitors
granted patentUS 12116343
Inhibitors of APOL1 and methods of using same
granted patentUS 12116606
Complement factor I-related compositions and methods
granted patentUS 12084438
GCN2 inhibitors and uses thereof
granted patentUS 12065432
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-me
granted patentUS 12060346
Inhibitors of APOL1 and methods of using same
granted patentUS 12053531
Materials and methods for treatment of Duchenne Muscular Dystrophy
granted patentUS 12049645
Differentiation of pancreatic endocrine cells
granted patentUS 12043843
Materials and methods for treatment of hemoglobinopathies
granted patentUS 12031150
Methods, compositions and kits for increasing genome editing efficiency
granted patentUS 12005127
DNA-PK inhibitors
granted patentUS 12006516
Differentiation of pancreatic endocrine cells
granted patentUS 11999971
Stem cell derived islet differentiation
granted patentUS 11992506
Stem cell derived pancreatic islet differentiation
granted patentUS 11980633
Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitor
granted patentUS 11951206
Cell housing device
granted patentUS 11951212
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance
granted